Can You Switch from Humira to Skyrizi for Crohn's Disease?
Yes, switching from Humira (adalimumab) to Skyrizi (risankizumab-rzaa) is possible for adults with moderate to severe Crohn's disease. Skyrizi is FDA-approved for this indication since June 2022, after showing efficacy in maintaining clinical remission in trials like ADVANCE and MOTIVATE.[1] Patients often transition due to loss of response to Humira, a TNF inhibitor, as Skyrizi targets IL-23 instead.
How Do Doctors Decide on a Switch?
Gastroenterologists assess based on disease activity, prior response, and side effects. Skyrizi is an option for those who've failed TNF blockers like Humira. Induction starts with IV doses at weeks 0, 4, and 8 (600 mg each), followed by 180 mg subcutaneous every 8 weeks for maintenance.[2] Switching typically happens after confirming active disease via endoscopy or imaging.
What Happens During the Transition Process?
No washout period is required, but timing varies. Many start Skyrizi soon after stopping Humira to avoid flares. Real-world data shows 40-60% achieve remission post-switch, though initial weeks carry flare risk.[3] Monitor with calprotectin levels or colonoscopy.
What Side Effects Differ Between Them?
Humira risks include infections and injection reactions; Skyrizi has similar infection warnings but lower rates of some TNF-related issues like demyelination. Common Skyrizi side effects: upper respiratory infections (10-13%), headache (5-10%), joint pain (5%). Long-term data is shorter for Skyrizi.[1][2]
How Effective Is Skyrizi After Humira Failure?
In trials, 40-45% of TNF-failure patients hit endoscopic response at week 24 vs. 20-25% placebo. At one year, 50%+ maintain remission. Better for fistulizing disease than some alternatives.[3]
When Does Skyrizi's Patent Expire?
Skyrizi's key composition-of-matter patent (US 8,778,885) expires in 2033, with others into 2034-2035. No biosimilars expected before then; AbbVie holds 17 Orange Book patents.[4]
What Are Other Switch Options if Skyrizi Isn't Ideal?
| Drug | Mechanism | Key Difference from Skyrizi |
|------|-----------|-----------------------------|
| Stelara (ustekinumab) | IL-12/23 inhibitor | IV induction, then every 8 weeks subQ; good for bridging but less IL-23 specific |
| Inflectra/Remicade biosimilars | TNF inhibitor | Cheaper than Humira but similar failure risk |
| Cimzia (certolizumab) | TNF inhibitor | Pegylated for less frequent dosing |
| Omvoh (mirikizumab) | IL-23 inhibitor | Newer oral-ish option, monthly subQ; similar efficacy |
Costs: Skyrizi ~$17,000/month pre-rebates; copay cards drop to $5 for eligible.[5]
What Risks Come with Switching?
Increased infection risk during transition (5-10% serious cases). Avoid in active TB or recent live vaccines. Pregnancy data limited; use contraception.[1]
[1]: FDA Skyrizi Label - https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761054s009lbl.pdf
[2]: Crohn's & Colitis Foundation Guidelines
[3]: ADVANCE/MOTIVATE Trials (NEJM 2022)
[4]: DrugPatentWatch.com - https://www.drugpatentwatch.com/p/tradename/SKYRIZI
[5]: AbbVie Patient Assistance